Lebenthal Global Advisors LLC Purchases 5,133 Shares of Novo Nordisk A/S (NYSE:NVO)

Lebenthal Global Advisors LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 32.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,736 shares of the company’s stock after purchasing an additional 5,133 shares during the quarter. Lebenthal Global Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,784,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter worth $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Albion Financial Group UT increased its position in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the period. Finally, Sound Income Strategies LLC lifted its stake in shares of Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.6 %

Shares of NVO stock opened at $86.55 on Monday. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $95.35 and a 200-day moving average of $114.80. The firm has a market cap of $388.39 billion, a P/E ratio of 28.04, a PEG ratio of 0.90 and a beta of 0.45.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NVO. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.